Get notified when RNAZ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Going Concern (new) — Company discloses substantial doubt about its ability to continue as a going concern due to financial condition and funding needs.
TransCode discloses Phase 1a trial results for TTX-MC138 amid going concern warning
Filed June 3, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Company disclosed substantial doubt about its ability to continue as a going concern, citing financial condition and urgent need for additional funding to support operations and clinical trials.
Item 8.01 verify on EDGAR → -
high
TransCode announced further results from its Phase 1a dose escalation clinical trial for TTX-MC138, its lead therapeutic candidate, though detailed trial data was provided only in the press release.
Item 8.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade RNAZ commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify